Goldman Sachs
SANA icon

Goldman Sachs’s Sana Biotechnology SANA Stock Holding History

Goldman Sachs’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.26M Sell
2,367,935
-813,180
-26% -$2.62M ﹤0.01% 3424
2026
Q1 		$9.16M Buy
3,181,115
+1,692,738
+114% +$6.67M ﹤0.01% 3141
2025
Q4 		$6.06M Buy
1,488,377
+806,285
+118% +$3.61M ﹤0.01% 3571
2025
Q3 		$2.42M Buy
682,092
+378,858
+125% +$1.37M ﹤0.01% 4315
2025
Q2 		$828K Sell
303,234
-250,171
-45% -$516K ﹤0.01% 4831
2025
Q1 		$930K Sell
553,405
-451,246
-45% -$1.26M ﹤0.01% 4735
2024
Q4 		$1.64M Buy
1,004,651
+154,653
+18% +$461K ﹤0.01% 4459
2024
Q3 		$3.54M Buy
849,998
+32,662
+4% +$172K ﹤0.01% 3663
2024
Q2 		$4.46M Sell
817,336
-35,440
-4% -$282K ﹤0.01% 3254
2024
Q1 		$8.53M Buy
852,776
+22,484
+3% +$168K ﹤0.01% 2621
2023
Q4 		$3.39M Buy
830,292
+215,650
+35% +$794K ﹤0.01% 3494
2023
Q3 		$2.38M Sell
614,642
-244,607
-28% -$1.31M ﹤0.01% 3635
2023
Q2 		$5.12M Sell
859,249
-116,845
-12% -$673K ﹤0.01% 3091
2023
Q1 		$3.19M Sell
976,094
-888,404
-48% -$3.55M ﹤0.01% 3474
2022
Q4 		$7.36M Buy
1,864,498
+453,630
+32% +$2.22M ﹤0.01% 2843
2022
Q3 		$8.47M Buy
1,410,868
+559,841
+66% +$4.04M ﹤0.01% 2653
2022
Q2 		$5.47M Buy
851,027
+255,738
+43% +$1.63M ﹤0.01% 3053
2022
Q1 		$4.92M Buy
595,289
+205,796
+53% +$1.66M ﹤0.01% 3372
2021
Q4 		$6.03M Buy
389,493
+116,168
+43% +$2.24M ﹤0.01% 3228
2021
Q3 		$6.16M Sell
273,325
-94,663
-26% -$1.99M ﹤0.01% 3180
2021
Q2 		$7.24M Buy
367,988
+211,202
+135% +$4.79M ﹤0.01% 3012
2021
Q1 		$5.25M Buy
+156,786
New +$5.11M ﹤0.01% 3095

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Goldman Sachs's SANA Position: Q2 2026 in Review

Goldman Sachs reduced its Sana Biotechnology (SANA) stake by 26% in Q2 2026, selling an estimated $2.62M and leaving 2,367,935 shares worth $8.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3424.

Goldman Sachs first reported a position in SANA in Q1 2021 and has held it in 22 quarters since. The position peaked at $9.16M in Q1 2026. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Goldman Sachs held 2,367,935 shares of Sana Biotechnology worth $8.26M as of Q2 2026.
  • Goldman Sachs sold 813,180 Sana Biotechnology shares in Q2 2026, an estimated $2.62M.
  • Sana Biotechnology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3424 holding.
  • Goldman Sachs first reported a position in Sana Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • Goldman Sachs's Sana Biotechnology position peaked at $9.16M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.